Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau
2007

Tramiprosate and Tau Aggregation in Alzheimer's Disease

publication 10 minutes Evidence: moderate

Author Information

Author(s): Santa-Maria Ismael, Hernández Félix, Del Rio Joaquín, Moreno Francisco J, Avila Jesús

Primary Institution: Centro de Biología Molecular 'Severo Ochoa' CSIC/UAM

Hypothesis

What is the effect of Tramiprosate on tau protein aggregation in Alzheimer's disease?

Conclusion

Tramiprosate promotes tau aggregation without affecting cell viability.

Supporting Evidence

  • Tramiprosate increases tau aggregation in both tau-transfected non-neuronal and neuronal cells.
  • 3-APS does not affect tau's binding to microtubules.
  • Cell viability remains unchanged with increasing concentrations of Tramiprosate.

Takeaway

Tramiprosate is a drug that can make tau proteins clump together, which is important for understanding Alzheimer's disease.

Methodology

The study tested the effects of Tramiprosate on tau aggregation in both non-neuronal and neuronal cells using various assays including immunofluorescence and Western blot.

Limitations

The study primarily focused on in vitro models, which may not fully represent in vivo conditions.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1750-1326-2-17

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication